# Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

> **NCT03621982** · PHASE1 · TERMINATED · sponsor: **ADC Therapeutics S.A.** · enrollment: 78 (actual)

## Conditions studied

- Head and Neck Cancer Squamous Cell Carcinoma
- Non-small Cell Lung Cancer
- Gastric Cancer
- Esophageal Cancer
- Pancreas Cancer
- Bladder Cancer
- Renal Cell Carcinoma
- Melanoma
- Triple-negative Breast Cancer
- Ovarian Cancer
- Colo-rectal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** ADCT-301
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03621982
- **Lead sponsor:** ADC Therapeutics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-09
- **Primary completion:** 2022-12-14
- **Final completion:** 2022-12-14
- **Target enrollment:** 78 (ACTUAL)
- **Why stopped:** Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study.
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03621982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03621982, "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03621982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*